{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:58:01Z","timestamp":1790913481815,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":210,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013514","name":"World Cancer Research Fund Netherlands","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002807","name":"Kankeronderzoekfonds Limburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101347","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T18:39:33Z","timestamp":1785695973000},"page":"101347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Associations of oxaliplatin dose, lean body mass, and sarcopenia with dose-limiting neuropathy in patients with colorectal cancer"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2808-5232","authenticated-orcid":false,"given":"Nadira R.","family":"Querido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J.L.","family":"Bours","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselot","family":"Valkenburg-van Iersel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinetta J.M.","family":"Beijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie O.","family":"Breukink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryska L.G.","family":"Janssen-Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.P.","family":"Keulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop L.M.","family":"Konsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matty P.","family":"Weijenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colinda C.J.M.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101347_bib0001","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.ctarc.2026.101347_bib0002","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/ijc.31785","article-title":"An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients","volume":"143","author":"Brouwer","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0003","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry","volume":"31","author":"Mols","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101347_bib0004","first-page":"1999","article-title":"A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration","volume":"22","author":"Beijers","year":"2014","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0005","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2015.11.011","article-title":"Chemotherapy-induced peripheral neuropathy: current status and progress","volume":"140","author":"Brewer","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101347_bib0006","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1200\/JCO.21.02538","article-title":"Adjuvant therapy for stage II colon cancer: ASCO guideline update","volume":"40","author":"Baxter","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101347_bib0007","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101347_bib0008","first-page":"33","article-title":"Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer","volume":"30","author":"Teng","year":"2022","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0009","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101347_bib0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1010639201787","article-title":"Body surface area as a determinant of pharmacokinetics and drug dosing","volume":"19","author":"Sawyer","year":"2001","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ctarc.2026.101347_bib0011","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101347_bib0012","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/annonc\/mdx810","article-title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","volume":"29","author":"Baracos","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101347_bib0013","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01635581.2014.894103","article-title":"Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer","volume":"66","author":"Barret","year":"2014","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0014","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/17512433.2017.1347503","article-title":"A review of body composition and pharmacokinetics in oncology","volume":"10","author":"Hopkins","year":"2017","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101347_bib0015","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1016\/j.clon.2021.05.011","article-title":"Body composition and dose-limiting toxicity in colorectal cancer chemotherapy treatment; a systematic review of the literature. Could muscle mass be the new Body surface area in chemotherapy dosing?","volume":"33","author":"Drami","year":"2021","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101347_bib0016","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","article-title":"Body composition as an independent determinant of 5-fluorouracil\u2013Based chemotherapy toxicity","volume":"13","author":"Prado","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101347_bib0017","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/j.cllc.2016.09.008","article-title":"Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non\u2013Small-cell lung cancer","volume":"18","author":"Sj\u00f8blom","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0018","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/cam4.621","article-title":"Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens","volume":"5","author":"Ali","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctarc.2026.101347_bib0019","first-page":"687","article-title":"Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy","volume":"23","author":"Jung","year":"2015","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0020","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1200\/JCO-24-02754","article-title":"Impact of lean body mass\u2013Based oxaliplatin dose calculation on neurotoxicity in adjuvant treatment of stage III colon cancer: results of the phase II randomized LEANOX trial","volume":"43","author":"Assenat","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101347_bib0021","first-page":"300","article-title":"Treatment adherence to adjuvant chemotherapy according to the new standard 3-month CAPOX regimen in high-risk stage II and stage III colon cancer: a population-based evaluation in the Netherlands","volume":"24","author":"Kvd","year":"2025","journal-title":"Clin. Colorectal. Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1385\/NI:5:1:11","article-title":"The extensible neuroimaging archive toolkit","volume":"5","author":"Marcus","year":"2007","journal-title":"Neuroinformatics."},{"key":"10.1016\/j.ctarc.2026.101347_bib0023","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.clnu.2020.01.008","article-title":"Automated body composition analysis of clinically acquired computed tomography scans using neural networks","volume":"39","author":"Paris","year":"2020","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ctarc.2026.101347_bib0024","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1139\/H08-075","article-title":"Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"10.1016\/j.ctarc.2026.101347_bib0025","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/jcsm.13080","article-title":"Body composition from single versus multi-slice abdominal computed tomography: Concordance and associations with colorectal cancer survival","volume":"13","author":"Anyene","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ctarc.2026.101347_bib0026","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"Martin","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101347_bib0027","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ijc.34149","article-title":"Translation of IDEA trial results into clinical practice: analysis of the implementation of a new guideline for colon cancer","volume":"151","author":"van Rooijen","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0028","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"10.1016\/j.ctarc.2026.101347_bib0029","series-title":"Common Terminology Criteria For Adverse Events (CTCAE) v 5.0","year":"2017"},{"key":"10.1016\/j.ctarc.2026.101347_bib0030","first-page":"156","article-title":"The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Care &","volume":"49","author":"Sangha","year":"2003","journal-title":"Research."},{"key":"10.1016\/j.ctarc.2026.101347_bib0031","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nut.2018.10.015","article-title":"The Maastricht FFQ: development and validation of a comprehensive food frequency questionnaire for the Maastricht study","volume":"62","author":"Van Dongen","year":"2019","journal-title":"Nutrition"},{"key":"10.1016\/j.ctarc.2026.101347_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1312","article-title":"Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy","volume":"9","author":"Molassiotis","year":"2019","journal-title":"Brain Behav."},{"key":"10.1016\/j.ctarc.2026.101347_bib0033","first-page":"1313","article-title":"Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV","volume":"21","author":"Vincenzi","year":"2013","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0034","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jclinepi.2021.08.001","article-title":"Glymour MM. Tutorial on directed acyclic graphs","volume":"142","author":"Digitale","year":"2022","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ctarc.2026.101347_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.112092","article-title":"Omission of main effects from regression models with a ratio variable as the focal exposure can result in bias and inflated type I error rates","volume":"190","author":"Valente","year":"2026","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ctarc.2026.101347_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2026.112257","article-title":"Response to \u201cratios are misleading exposure variables that compromise a regression model unless fundamental scaling assumptions are satisfied: a comment on Valente et al","volume":"195","author":"Valente","year":"2026","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ctarc.2026.101347_bib0037","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","article-title":"Principles of confounder selection","volume":"34","author":"VanderWeele","year":"2019","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.ctarc.2026.101347_bib0038","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ans.18812","article-title":"The association of body composition on chemotherapy toxicities in non-metastatic colorectal cancer patients: a systematic review","volume":"94","author":"Choi","year":"2024","journal-title":"ANZ. J. Surg."},{"key":"10.1016\/j.ctarc.2026.101347_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17987\/jcsm-cr.v3i1.46","article-title":"Side-effects related to adjuvant CAPOX treatment for colorectal cancer are associated with intermuscular fat area, not with total skeletal muscle or fat, a retrospective observational study","volume":"3","author":"Plas","year":"2018","journal-title":"JCSM. Clin. Rep."},{"key":"10.1016\/j.ctarc.2026.101347_bib0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jcsm.12371","article-title":"Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy","volume":"10","author":"Dijksterhuis","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ctarc.2026.101347_bib0041","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1186\/s12885-018-4860-1","article-title":"Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients","volume":"18","author":"Botsen","year":"2018","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0042","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1002\/cncr.30950","article-title":"Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: the C-SCANS study","volume":"123","author":"Cespedes Feliciano","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2026.101347_bib0043","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4143\/crt.2010.42.4.185","article-title":"Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer","volume":"42","author":"Baek","year":"2010","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101347_bib0044","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S1470-2045(18)30093-7","article-title":"3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial","volume":"19","author":"Iveson","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101347_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102063","article-title":"The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial","volume":"8","author":"Lemanska","year":"2023","journal-title":"ESMo Open."},{"key":"10.1016\/j.ctarc.2026.101347_bib0046","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/jpen.2415","article-title":"Prevalence of sarcopenia in patients with solid tumors: a meta-analysis based on 81,814 patients","volume":"46","author":"Surov","year":"2022","journal-title":"J. Parenter. Enteral Nutr."},{"key":"10.1016\/j.ctarc.2026.101347_bib0047","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac058","article-title":"Espinosa da Silva C. Sex and gender differences in anticancer treatment toxicity: A call for revisiting drug dosing in oncology","volume":"163","author":"\u00d6zdemir","year":"2022","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctarc.2026.101347_bib0048","first-page":"92","article-title":"Importance of sex-dependent differences for dosing selection and optimization of chemotherapeutic drugs","volume":"70","author":"Seydoux","year":"2025","journal-title":"Chemotherapy (Los. Angel)"},{"key":"10.1016\/j.ctarc.2026.101347_bib0049","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/cam4.621","article-title":"Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens","volume":"5","author":"Ali","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctarc.2026.101347_bib0050","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/jcm9082400","article-title":"Long-term prevalence of sensory chemotherapy-induced peripheral neuropathy for 5 years after adjuvant FOLFOX chemotherapy to treat colorectal cancer: a multicenter cross-sectional study","volume":"9","author":"Selvy","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ctarc.2026.101347_bib0051","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.ctarc.2026.101347_bib0052","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","article-title":"Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer","volume":"34","author":"Blauwhoff-Buskermolen","year":"2016","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101347_bib0053","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcsm.12337","article-title":"Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients","volume":"9","author":"Kurk","year":"2018","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ctarc.2026.101347_bib0054","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur. J. Cancer"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:51:14Z","timestamp":1790913074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":54,"alternative-id":["S2468294226002583"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101347","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations of oxaliplatin dose, lean body mass, and sarcopenia with dose-limiting neuropathy in patients with colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101347"}}